Kevin Stankiewicz

Why we’re lowering our Bristol Myers price target despite an earnings beat, guidance raise

Shares of Bristol Myers Squibb fell modestly after the drugmaker's better-than-expected first-quarter results.

Read More »

Is this 2-day stock market surge for real? Here’s a look at what’s driving the rally

The sigh of relief is playing out within our portfolio.

Read More »

Is this 2-day stock market surge for real? Here’s a look at what’s driving the rally

The sigh of relief is playing out within our portfolio.

Read More »

Danaher’s quarterly results show signs of life, and the struggling stock soars

Count us among the Danaher investors breathing a sigh of relief.

Read More »

Jim Cramer says CEOs are reluctant to talk publicly during second Trump presidency

"People who have historically been on the record will talk with me and say, 'Look, I've got to talk off…

Read More »

Eli Lilly shares surge on new obesity pill data. What it means for the stock from here

Jim Cramer said Eli Lilly's new trial data has turned the obesity market into a 'one-horse race.'

Read More »

Abbott Labs shares surge on earnings and a big sign of confidence in the business

Abbott's strong stock performance continued Wednesday after a first-quarter earnings beat and a guidance reaffirmation.

Read More »

It’s a different world for Nvidia’s stock under Trump. The chipmaker’s latest China hit proves that

Nvidia shares tumbled Wednesday morning after the chipmaker disclosed its made-for-China chips face new restrictions.

Read More »

Goldman’s earnings provide reasons to believe in the stock despite a blurry backdrop

We're reiterating our buy-equivalent rating on the investment bank.

Read More »

We’re sticking with BlackRock after it delivered solid earnings in a tough market

The asset manager is controlling what it can control.

Read More »